Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;13(3):1647-1654.
doi: 10.3892/ol.2017.5620. Epub 2017 Jan 18.

Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer

Magda Palka  1 , Antonio Sanchez  1 , Mar Córdoba  2 , Gema Díaz Nuevo  3 , Andrés Varela De Ugarte  2 , Blanca Cantos  1 , Miriam Méndez  1 , Virginia Calvo  1 , Constanza Maximiano  1 , Mariano Provencio  1
Affiliations

Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer

Magda Palka et al. Oncol Lett. 2017 Mar.

Abstract

Survival rates in patients with stage IIIA non-small cell lung cancer (NSCLC) remain low despite curative treatment. This is due to tumor recurrence at distant sites. The aim of neoadjuvant chemotherapy (NA-CT) is to eradicate occult micrometastatic disease and improve survival in patients that are not candidates for surgery following induction therapy. A total of 21 patients with ipsilateral mediastinal node involvement (N2) with potentially resectable disease, who had been diagnosed with stage IIIA (T1-3 N1-2 and T4N0) NSCLC and who had received cisplatin and vinorelbine as induction treatment were included in this retrospective study. Patients who responded to the treatment underwent surgery, and those who were unresponsive received radical radiotherapy. Follow-up was conducted between March 2008 and April 2014. The median age of patients was 61 years, and all patients exhibited a good Eastern Cooperative Oncology Group performance status. The majority of patients were histologically diagnosed with adenocarcinoma (48%) or squamous cell carcinoma (38%), which was a poor prognostic factor for overall survival (OS). A total of 7 patients underwent surgery (of which 6 were down-staged), with a 3-year survival rate of 42.8%. The most significant factor associated with response to induction treatment was multistation nodal involvement. The complete resection rate for surgical patients was 85.7%. Unresectable patients had a 3-year survival rate of 25.8%. OS time for the whole cohort was 28.5 months, and the 3- and 5-year OS rates were 28.5% and 4.7%, respectively. CT-induced toxicity did not affect any treatment regime or surgical procedures. In conclusion, the use of cisplatin plus vinorelbine is feasible in a neoadjuvant setting, with good response rates and acceptable toxicity. Multistation N2 involvement is the main prognostic factor for a poor response to induction treatment.

Keywords: cisplatin; induction treatment; neoadjuvant chemotherapy; stage III non-small cell lung cancer; survival; vinorelbine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Progression-free survival. A Kaplan-Meier graph for progression-free survival of the entire patient cohort. The 3-year disease free survival was 23.8%, which entailed a median of 19.4 months progression-free survival.
Figure 2.
Figure 2.
Overall survival. The Kaplan-Meier graph shows overall survival of the entire patient cohort. The 3-year overall survival rate was 28.5%, which implies a median overall survival of 28.5 months.
See this image and copyright information in PMC

References

    1. American Cancer Society, corp-author. Lung cancer (Non-small cell) Atlanta, GA, USA: 2016.
    1. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E., Jr The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol. 2012;4:128–134. doi: 10.4329/wjr.v4.i4.128. - DOI - PMC - PubMed
    1. Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: Systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 2009;4:1380–1388. doi: 10.1097/JTO.0b013e3181b9ecca. - DOI - PubMed
    1. Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35–42. doi: 10.1200/JCO.2009.23.2272. - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, et al., editors. SEER Cancer Statistics Review. National Cancer Institute; Bethesda, MD: 1975–2013. Accessed September 1, 2016.